Betamethasone valerate, clotrimazole.
Each 100 g contains: Betamethasone valerate eq. to Betamethasone 0.1 g, Clotrimazole 1 g.
Betamethasone: Corticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger (mRNA) and subsequent protein synthesis of various inhibitory enzymes responsible for anti-inflammatory effects of topical corticosteroids. These anti-inflammatory effects include inhibition of early processes such as edema, fibrin deposition, capillary dilatation, movement of phagocytes into the area, and phagocytic activities. Later processes, such as capillary production, collagen deposition, and keloid formation, are also inhibited by corticosteroids. The overall actions of topical corticosteroids are catabolic. Absorbed systemically across the stratum corneum.
Clotrimazole: Fungistatic; may be fungicidal, depending on concentration; inhibits biomembrane of ergosterol or other sterols, damaging the fungal cell wall membrane and altering its permeability; as a result, loss of essential intracellular elements may occur; also inhibits biosynthesis of triglycerides and phospholipids by fungi; in addition, inhibits oxidative and perioxidative enzyme activity, resulting in intracellular build up of toxic concentrations of hydrogen peroxide, which may contribute to deterioration of subcellular organelles and cellular necrosis. In Candida albicans, inhibits transformation of blastospores into invasive mycelial form. Absorption; dermal penetration; minimal systemic absorption.
Inflammatory manifestations of corticosteroid-responsive dermatoses when complicated by secondary fungal infections or when such complication is expected.
Adult and adolescent: Affected areas and surrounding skin, two times a day in the morning and evening.
Infants and children up to 12 years: Safety and efficacy have not been established.
Children 12 years and above: See adult and adolescent dose.
OR AS PRESCRIBED BY THE PHYSICIAN.
Allergy to corticosteroid, infection or Herpes simplex at treatment site and pre-existing skin atrophy.
Not applying occlusive dressing over this medication unless directed to do so by physician; wearing loose-fitting clothing when using on inguinal area.
Compliance with full course of therapy; not using more often or for longer than directed by physician; excessive use on thin skin areas may result in skin atrophy and stretch marks.
Use in Children: May cause HPA axis suppression, Cushing's syndrome, intracranial hypertension, or growth suppression. Other medical problems, especially eczema vaccinatum, herpes simplex, tubercular infections of the skin, vaccinia, varicella or other viral infections of the skin.
Pregnancy: Not recommended in pregnancy because of possibility of teratogenicity, especially when used on extensive surface areas, in large amounts, or for prolonged periods of time.
Breast-feeding: May cause systemic effects, such as growth suppression.
Signs of potential side effects, especially hypersensitivity and long-term effects, including skin atrophy.
Store at temperature not more than 30°C, in a tight-light resistant container. Protect from heat and freezing.
D07BC01 - betamethasone and antiseptics ; Belongs to the class of potent (group III) corticosteroids, in combination with antiseptics. Used in the treatment of dermatological diseases.